Biogen | BIIB - Przychody Ze Sprzedaży





Obroty Zmiana Data
AbbVie USD 15B 1.62B 2026-03
Acadia Pharmaceuticals USD 268.06M 15.94M 2026-03
ALKERMES USD 392.91M 8.41M 2026-03
Amgen USD 8.62B 1.28B 2026-03
Bayer EUR 13.41B 1.97B 2026-03
Biogen USD 2.25B 30M 2026-03
BioMarin Pharmaceutical USD 766M 109M 2026-03
Bristol-Myers Squibb USD 11.49B 1.01B 2026-03
Eli Lilly USD 19.8B 500M 2026-03
Esperion Therapeutics USD 168.45M 81.14M 2025-12
Gilead Sciences USD 7B 930M 2026-03
Incyte USD 1.27B 240M 2026-03
Merck USD 16.29B 110M 2026-03
Moderna USD 389M 289M 2026-03
Neurocrine Biosciences USD 811M 5.5M 2026-03
Novartis USD 13.11B 226M 2026-03
Pfizer USD 14.5B 3.08B 2026-03
PTC Therapeutics USD 273M 108.3M 2026-03
Puma Biotechnology USD 80.54M 33.46M 2024-09
Regeneron Pharmaceuticals USD 3.6B 280M 2026-03
Sangamo BioSciences USD 356K 125K 2024-06
Sanofi EUR 11.24B 60M 2026-03
Sanofi EUR 12.14B 65M 2026-03
Sarepta Therapeutics USD 730.8M 287.9M 2026-03
Teva Pharmaceutical Industries USD 11.77B 2.86B 2026-03
Ultragenyx Pharmaceutical USD 136M 71M 2026-03
United Therapeutics USD 781.5M 8.7M 2026-03
Vertex Pharmaceuticals USD 2.99B 200M 2026-03